Reframing recalcitrance for small-cell lung cancer

被引：305

作者：

Blackhall, F. H. ^{[1
]}

机构：

[1] Christie Hosp NHS Trust Med Oncol, Manchester, Lancs, England

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷 / 07期

关键词：

CONVERT;

D O I：

10.1016/j.annonc.2021.03.207

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：829 / 830

页数：2

共 19 条

[1] Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse
Almodovar, Karinna
Iams, Wade T.
Meador, Catherine B.
Zhao, Zhiguo
York, Sally
Horn, Leora
Yan, Yingjun
Hernandez, Jennifer
Chen, Heidi
Shyr, Yu
Lim, Lee P.
Raymond, Christopher K.
Lovly, Christine M.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (01) : 112 - 123
[2] [Anonymous], 2014, CANC INCIDENCE 5 CON
[3] [Anonymous], 2020, BRIST MYERS SQUIBB S
[4] [Anonymous], 2021, MERCK PROV UPD KEYTR
[5] Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
Blackhall, Fiona
Jao, Kevin
Greillier, Laurent
Cho, Byoung Chul
Penkov, Konstantin
Reguart, Noemi
Majem, Margarita
Nackaerts, Kristiaan
Syrigos, Konstantinos
Hansen, Karin
Schuette, Wolfgang
Cetnar, Jeremy
Cappuzzo, Federico
Okamoto, Isamu
Erman, Mustafa
Langer, Seppo W.
Kato, Terufumi
Groen, Harry
Sun, Zhaowen
Luo, Yan
Tanwani, Poonam
Caffrey, Laura
Komarnitsky, Philip
Reinmuth, Niels
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1547 - 1558
[6] Reframing recalcitrance for small-cell lung cancer
Blackhall, F. H.
[J]. ANNALS OF ONCOLOGY, 2021, 32 (07) : 829 - 830
[7] Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Faivre-Finn, Corinne
Snee, Michael
Ashcroft, Linda
Appel, Wiebke
Barlesi, Fabrice
Bhatnagar, Adityanarayan
Bezjak, Andrea
Cardenal, Felipe
Fournel, Pierre
Harden, Susan
Le Pechoux, Cecile
McMenemin, Rhona
Mohammed, Nazia
O'Brien, Mary
Pantarotto, Jason
Surmont, Veerle
Van Meerbeeck, Jan P.
Woll, Penella J.
Lorigan, Paul
Blackhall, Fiona
[J]. LANCET ONCOLOGY, 2017, 18 (08) : 1116 - 1125
[8] Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Gay, Carl M.
Stewart, C. Allison
Park, Elizabeth M.
Diao, Lixia
Groves, Sarah M.
Heeke, Simon
Nabet, Barzin Y.
Fujimoto, Junya
Solis, Luisa M.
Lu, Wei
Xi, Yuanxin
Cardnell, Robert J.
Wang, Qi
Fabbri, Giulia
Cargill, Kasey R.
Vokes, Natalie, I
Ramkumar, Kavya
Zhang, Bingnan
Della Corte, Carminia M.
Robson, Paul
Swisher, Stephen G.
Roth, Jack A.
Glisson, Bonnie S.
Shames, David S.
Wistuba, Ignacio I.
Wang, Jing
Quaranta, Vito
Minna, John
Heymach, John, V
Byers, Lauren Averett
[J]. CANCER CELL, 2021, 39 (03) : 346 - +
[9] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Horn, L.
Mansfield, A. S.
Szczesna, A.
Havel, L.
Krzakowski, M.
Hochmair, M. J.
Huemer, F.
Losonczy, G.
Johnson, M. L.
Nishio, M.
Reck, M.
Mok, T.
Lam, S.
Shames, D. S.
Liu, J.
Ding, B.
Lopez-Chavez, A.
Kabbinavar, F.
Lin, W.
Sandler, A.
Liu, S. V.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) : 2220 - 2229
[10] Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey
Levy, Antonin
Hendriks, Lizza E. L.
Le Pechoux, Cecile
Falk, Sally
Besse, Benjamin
Novello, Silvia
Dingemans, Anne-Marie C.
Hasan, Baktiar
Reck, Martin
Berghmans, Thierry
Faivre-Finn, Corinne
[J]. LUNG CANCER, 2019, 136 : 145 - 147

← 1 2 →